Identification of a novel BACE1 inhibitor, timosaponin A-III, for treatment of Alzheimer's disease by a cell extraction and chemogenomics target knowledgebase-guided method

Hai-Qiao Wang,Min Liu,Liang Wang,Fen Lan,Yi-Han Zhang,Jin-Er Xia,Zhen-Dong Xu,Hai Zhang
DOI: https://doi.org/10.1016/j.phymed.2020.153244
IF: 6.656
2020-08-01
Phytomedicine
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Rhizoma Anemarrhenae (RA) has been conventionally used for treatment of Alzheimer's disease (AD) in Traditional Chinese Medicine, and thus, the active components from RA can be screened.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>This research aimed to identify the active components of RA and their targets and further clarify the molecular mechanisms underlying its anti-AD activity.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>First, the potential active compounds from RA were screened by neurocyte extraction and micro-dialysis methods. Second, the potential targets were predicted by a chemogenomics target knowledgebase and further explored by surface plasmon resonance and enzyme activity assays. Third, the pharmacological effects were evaluated by employing APP/PS1 transgenic mice and SH-SY5Y-APP cells. ELISAs and Western blot analyses were used to evaluate the expression of key molecules in the amyloidogenic and NMDAR/ERK pathways.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Timosaponin A-III (TA-III) was screened and identified as a potential active component for the anti-AD activity, and BACE1 was proven to be a potential high-affinity target. Enzyme kinetic analysis showed that TA-III had strong noncompetitive inhibitory activity against BACE1. The <em>in vitro</em> and <em>in vivo</em> assays indicated that TA-III had pharmacological effects through improving memory impairment, reducing Aβ aggregation via the amyloidogenic pathway and preventing neuronal impairment through downregulating the NMDAR/ERK signaling pathway.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>TA-III targets BACE1 to reduce Aβ aggregation through down-regulating the NMDAR/ERK pathway for treating AD.</p>
pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences
What problem does this paper attempt to address?